O	O	O	0	6	Potent	Potent	B-NP	JJ	O	6	NMOD	O
O	O	O	7	11	gene	gene	I-NP	NN	O	6	NMOD	O
O	O	O	12	22	regulatory	regulatory	I-NP	JJ	O	5	AMOD	O
O	O	O	23	26	and	and	I-NP	CC	O	5	AMOD	O
O	O	O	27	44	antiproliferative	antiproliferative	I-NP	JJ	O	6	NMOD	O
O	O	O	45	55	activities	activity	I-NP	NNS	O	0	ROOT	O
O	O	O	56	58	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	59	61	20	20	B-NP	CD	O	11	NMOD	O
O	O	O	61	62	-	-	I-NP	HYPH	O	11	NMOD	O
O	O	O	62	68	methyl	methyl	I-NP	NN	O	11	NMOD	O
O	O	O	69	78	analogues	analogue	I-NP	NNS	O	7	PMOD	O
O	O	O	79	81	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	82	83	1	1	B-NP	CD	O	15	AMOD	O
O	O	O	83	84	,	,	I-NP	,	O	15	P	O
O	O	O	84	86	25	25	I-NP	CD	O	17	NMOD	O
O	O	O	87	103	dihydroxyvitamin	dihydroxyvitamin	I-NP	NN	O	17	NMOD	O
O	O	O	104	106	D3	D3	I-NP	NN	O	12	PMOD	O
O	O	O	106	107	.	.	O	.	O	6	P	O

O	O	O	109	112	The	The	B-NP	DT	O	4	NMOD	O
O	O	O	113	123	biological	biological	I-NP	JJ	O	4	NMOD	O
O	O	O	124	130	active	active	I-NP	JJ	O	4	NMOD	O
O	O	O	131	135	form	form	I-NP	NN	O	19	SUB	O
O	O	O	136	138	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	139	146	vitamin	vitamin	B-NP	NN	O	7	NMOD	O
O	O	O	147	149	D3	D3	I-NP	NN	O	14	NMOD	O
O	O	O	149	150	,	,	O	,	O	14	P	O
O	O	O	151	152	1	1	B-NP	CD	O	14	NMOD	O
O	O	O	152	153	,	,	I-NP	,	O	14	P	O
O	O	O	153	155	25	25	I-NP	CD	O	14	NMOD	O
O	O	O	155	156	-	-	I-NP	HYPH	O	14	NMOD	O
O	O	O	156	172	dihydroxyvitamin	dihydroxyvitamin	I-NP	NN	O	14	NMOD	O
O	O	O	173	175	D3	D3	I-NP	NN	O	5	PMOD	O
O	O	O	176	177	(	(	O	(	O	17	DEP	O
O	O	O	177	179	VD	VD	B-NP	NN	O	17	DEP	O
O	O	O	179	180	)	)	O	)	O	14	NMOD	O
O	O	O	180	181	,	,	O	,	O	4	P	O
O	O	O	182	191	regulates	regulate	B-VP	VBZ	O	0	ROOT	O
O	O	O	192	200	cellular	cellular	B-NP	JJ	O	23	NMOD	O
O	O	O	201	207	growth	growth	B-NP	NN	O	23	NMOD	O
O	O	O	208	211	and	and	O	CC	O	23	NMOD	O
O	O	O	212	227	differentiation	differentiation	B-NP	NN	O	19	OBJ	O
O	O	O	227	228	.	.	O	.	O	19	P	O

O	O	O	229	233	This	This	B-NP	DT	O	2	SUB	O
O	O	O	234	242	provides	provide	B-VP	VBZ	O	0	ROOT	O
O	O	O	243	246	the	the	B-NP	DT	O	4	NMOD	O
O	O	O	247	254	hormone	hormone	I-NP	NN	O	2	OBJ	O
O	O	O	255	259	with	with	B-PP	IN	O	4	NMOD	O
O	O	O	260	262	an	an	B-NP	DT	O	9	NMOD	O
O	O	O	263	274	interesting	interesting	I-NP	JJ	O	9	NMOD	O
O	O	O	275	286	therapeutic	therapeutic	I-NP	JJ	O	9	NMOD	O
O	O	O	287	296	potential	potential	I-NP	NN	O	5	PMOD	O
O	O	O	296	297	.	.	O	.	O	2	P	O

O	O	O	298	305	However	However	B-ADVP	RB	O	4	VMOD	O
O	O	O	305	306	,	,	O	,	O	4	P	O
O	O	O	307	320	hypercalcemia	hypercalcemia	B-NP	NN	O	4	SUB	O
O	O	O	321	323	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	324	325	a	a	B-NP	DT	O	7	NMOD	O
O	O	O	326	330	side	side	I-NP	NN	O	7	NMOD	O
O	O	O	331	337	effect	effect	I-NP	NN	O	15	SUB	O
O	O	O	337	338	,	,	O	,	O	7	P	O
O	O	O	339	344	which	which	B-NP	WDT	O	7	NMOD	O
O	O	O	345	347	is	be	B-VP	VBZ	O	9	SBAR	O
O	O	O	348	354	caused	cause	I-VP	VBN	O	10	VC	O
O	O	O	355	357	by	by	B-PP	IN	O	11	VMOD	O
O	O	O	358	360	VD	VD	B-NP	NN	O	12	PMOD	O
O	O	O	360	361	'	'	O	''	O	13	NMOD	O
O	O	O	361	362	s	s	B-VP	VBZ	O	4	VMOD	O
O	O	O	363	372	classical	classical	B-NP	JJ	O	17	NMOD	O
O	O	O	373	379	action	action	I-NP	NN	O	15	OBJ	O
O	O	O	379	380	,	,	O	,	O	15	P	O
O	O	O	381	384	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	385	395	regulation	regulation	I-NP	NN	O	15	VMOD	O
O	O	O	396	398	of	of	B-PP	IN	O	20	NMOD	O
O	O	O	399	406	calcium	calcium	B-NP	NN	O	23	NMOD	O
O	O	O	407	418	homeostasis	homeostasis	I-NP	NN	O	21	PMOD	O
O	O	O	418	419	.	.	O	.	O	4	P	O

O	O	O	420	424	This	This	B-NP	DT	O	2	SUB	O
O	O	O	425	429	made	make	B-VP	VBD	O	0	ROOT	O
O	O	O	430	433	the	the	B-NP	DT	O	4	NMOD	O
O	O	O	434	438	need	need	I-NP	NN	O	2	OBJ	O
O	O	O	439	442	for	for	B-PP	IN	O	4	NMOD	O
O	O	O	443	445	VD	VD	B-NP	NN	O	7	NMOD	O
O	O	O	446	455	analogues	analogue	I-NP	NNS	O	5	PMOD	O
O	O	O	456	460	with	with	B-PP	IN	O	7	NMOD	O
O	O	O	461	472	selectively	selectively	B-NP	RB	O	10	AMOD	O
O	O	O	473	482	increased	increase	I-NP	VBN	O	13	NMOD	O
O	O	O	483	487	cell	cell	I-NP	NN	O	13	NMOD	O
O	O	O	488	498	regulatory	regulatory	I-NP	JJ	O	13	NMOD	O
O	O	O	499	509	properties	property	I-NP	NNS	O	8	PMOD	O
O	O	O	509	510	.	.	O	.	O	2	P	O

O	O	O	511	518	Studies	Study	B-NP	NNS	O	7	SUB	O
O	O	O	519	523	with	with	B-PP	IN	O	1	NMOD	O
O	O	O	524	526	20	20	B-NP	CD	O	6	NMOD	O
O	O	O	526	527	-	-	I-NP	HYPH	O	6	NMOD	O
O	O	O	527	530	epi	epi	I-NP	NN	O	6	NMOD	O
O	O	O	531	540	analogues	analogue	I-NP	NNS	O	2	PMOD	O
O	O	O	541	548	pointed	point	B-VP	VBD	O	0	ROOT	O
O	O	O	549	552	out	out	B-PRT	RP	O	7	VMOD	O
O	O	O	553	556	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	557	567	importance	importance	I-NP	NN	O	7	OBJ	O
O	O	O	568	570	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	571	574	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	575	581	carbon	carbon	I-NP	NN	O	16	NMOD	O
O	O	O	581	582	-	-	I-NP	HYPH	O	16	NMOD	O
O	O	O	582	584	20	20	I-NP	CD	O	16	NMOD	O
O	O	O	585	593	position	position	I-NP	NN	O	11	PMOD	O
O	O	O	594	597	and	and	O	CC	O	7	VMOD	O
O	O	O	598	601	led	lead	B-VP	VBD	O	7	VMOD	O
O	O	O	602	604	to	to	B-PP	TO	O	18	VMOD	O
O	O	O	605	608	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	609	620	development	development	I-NP	NN	O	19	PMOD	O
O	O	O	621	623	of	of	B-PP	IN	O	21	NMOD	O
O	O	O	624	626	20	20	B-NP	CD	O	26	NMOD	O
O	O	O	626	627	-	-	I-NP	HYPH	O	26	NMOD	O
O	O	O	627	633	methyl	methyl	I-NP	NN	O	26	NMOD	O
O	O	O	634	645	derivatives	derivative	I-NP	NNS	O	22	PMOD	O
O	O	O	646	648	of	of	B-PP	IN	O	26	NMOD	O
O	O	O	649	651	VD	VD	B-NP	NN	O	27	PMOD	O
O	O	O	651	652	.	.	O	.	O	7	P	O

O	O	O	653	655	In	In	B-PP	IN	O	31	VMOD	O
O	O	O	656	660	this	this	B-NP	DT	O	3	NMOD	O
O	O	O	661	667	report	report	I-NP	NN	O	1	PMOD	O
O	O	O	668	671	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	672	682	biological	biological	I-NP	JJ	O	6	NMOD	O
O	O	O	683	693	properties	property	I-NP	NNS	O	1	PMOD	O
O	O	O	694	696	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	697	700	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	701	710	compounds	compound	I-NP	NNS	O	7	PMOD	O
O	O	O	711	719	ZK161422	ZK161422	I-NP	NN	O	12	NMOD	O
O	O	O	720	723	and	and	I-NP	CC	O	12	NMOD	O
O	O	O	724	732	ZK157202	ZK157202	I-NP	NN	O	9	NMOD	O
O	O	O	732	733	,	,	O	,	O	9	P	O
O	O	O	734	739	which	which	B-NP	WDT	O	9	NMOD	O
O	O	O	740	743	are	be	B-VP	VBP	O	27	VMOD	O
O	O	O	744	746	20	20	B-NP	CD	O	27	NMOD	O
O	O	O	746	747	-	-	I-NP	HYPH	O	27	NMOD	O
O	O	O	747	753	methyl	methyl	I-NP	NN	O	27	NMOD	O
O	O	O	753	754	-	-	B-NP	HYPH	O	18	P	O
O	O	O	755	758	and	and	I-NP	CC	O	27	NMOD	O
O	O	O	759	761	20	20	I-NP	CD	O	27	NMOD	O
O	O	O	761	762	-	-	I-NP	HYPH	O	27	NMOD	O
O	O	O	762	768	methyl	methyl	I-NP	NN	O	27	NMOD	O
O	O	O	768	769	-	-	B-NP	HYPH	O	27	NMOD	O
O	O	O	769	771	23	23	I-NP	CD	O	27	NMOD	O
O	O	O	771	772	-	-	I-NP	HYPH	O	27	NMOD	O
O	O	O	772	784	eneanalogues	eneanalogue	I-NP	NNS	O	14	NMOD	O
O	O	O	784	785	,	,	O	,	O	31	P	O
O	O	O	786	798	respectively	respectively	B-ADVP	RB	O	31	VMOD	O
O	O	O	798	799	,	,	O	,	O	31	P	O
O	O	O	800	804	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	805	809	been	be	I-VP	VBN	O	31	VC	O
O	O	O	810	818	analyzed	analyze	I-VP	VBN	O	32	VC	O
O	O	O	819	821	in	in	B-PP	IN	O	33	VMOD	O
O	O	O	822	832	comparison	comparison	B-NP	NN	O	34	PMOD	O
O	O	O	833	837	with	with	B-PP	IN	O	35	NMOD	O
O	O	O	838	840	VD	VD	B-NP	NN	O	36	PMOD	O
O	O	O	840	841	.	.	O	.	O	31	P	O

O	O	O	842	846	Both	Both	B-NP	DT	O	2	NMOD	O
O	O	O	847	856	compounds	compound	I-NP	NNS	O	3	SUB	O
O	O	O	857	861	show	show	B-VP	VBP	O	0	ROOT	O
O	O	O	862	867	about	about	B-NP	RB	O	9	NMOD	O
O	O	O	868	869	2	2	I-NP	CD	O	4	AMOD	O
O	O	O	869	870	-	-	I-NP	HYPH	O	7	AMOD	O
O	O	O	870	874	fold	fold	I-NP	RB	O	4	AMOD	O
O	O	O	875	880	lower	low	I-NP	JJR	O	4	AMOD	O
O	O	O	881	889	affinity	affinity	I-NP	NN	O	3	OBJ	O
O	O	O	890	892	to	to	B-PP	TO	O	9	NMOD	O
O	O	O	893	896	the	the	B-NP	DT	O	13	NMOD	O
T1	B-Protein	B-Protein	897	899	VD	VD	I-NP	NN	B-protein	13	NMOD	B-protein
T1	I-Protein	I-Protein	900	908	receptor	receptor	I-NP	NN	I-protein	10	PMOD	I-protein
O	O	O	909	910	(	(	O	(	O	16	DEP	O
T2	B-Protein	B-Protein	910	913	VDR	VDR	B-NP	NN	B-protein	16	DEP	B-protein
O	O	O	913	914	)	)	O	)	O	13	NMOD	O
O	O	O	915	919	than	than	B-PP	IN	O	9	NMOD	O
O	O	O	920	922	VD	VD	B-NP	NN	O	17	PMOD	O
O	O	O	922	923	.	.	O	.	O	3	P	O

O	O	O	924	931	However	However	B-ADVP	RB	O	10	VMOD	O
O	O	O	931	932	,	,	O	,	O	10	P	O
O	O	O	933	941	compared	compare	B-PP	VBN	O	10	VMOD	O
O	O	O	942	944	to	to	B-PP	TO	O	3	VMOD	O
O	O	O	945	947	VD	VD	B-NP	NN	O	4	PMOD	O
O	O	O	947	948	,	,	O	,	O	10	P	O
O	O	O	949	954	their	their	B-NP	PRP$	O	9	NMOD	O
O	O	O	955	972	antiproliferative	antiproliferative	I-NP	JJ	O	9	NMOD	O
O	O	O	973	979	effect	effect	I-NP	NN	O	10	SUB	O
O	O	O	980	982	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	983	985	up	up	B-NP	IN	O	15	AMOD	O
O	O	O	986	988	to	to	I-NP	TO	O	11	AMOD	O
O	O	O	989	991	30	30	I-NP	CD	O	11	AMOD	O
O	O	O	991	992	-	-	I-ADVP	HYPH	O	11	P	O
O	O	O	992	996	fold	fold	I-ADVP	RB	O	16	AMOD	O
O	O	O	997	1003	higher	high	B-ADVP	JJR	O	30	AMOD	O
O	O	O	1004	1006	on	on	B-PP	IN	O	16	AMOD	O
O	O	O	1007	1012	human	human	B-NP	JJ	B-cell_type	22	NMOD	B-cell_type
O	O	O	1013	1023	peripheral	peripheral	I-NP	JJ	I-cell_type	22	NMOD	I-cell_type
O	O	O	1024	1029	blood	blood	I-NP	NN	I-cell_type	22	NMOD	I-cell_type
O	O	O	1030	1041	mononuclear	mononuclear	I-NP	JJ	I-cell_type	22	NMOD	I-cell_type
O	O	O	1042	1047	cells	cell	I-NP	NNS	I-cell_type	17	PMOD	I-cell_type
O	O	O	1048	1051	and	and	O	CC	O	25	DEP	O
O	O	O	1052	1056	even	even	B-NP	RB	O	25	DEP	O
O	O	O	1057	1059	up	up	I-NP	IN	O	29	AMOD	O
O	O	O	1060	1062	to	to	I-NP	TO	O	25	AMOD	O
O	O	O	1063	1066	300	300	I-NP	CD	O	25	AMOD	O
O	O	O	1066	1067	-	-	O	HYPH	O	25	P	O
O	O	O	1067	1071	fold	fold	B-ADJP	RB	O	30	AMOD	O
O	O	O	1072	1078	higher	high	I-ADJP	JJR	O	10	PRD	O
O	O	O	1079	1081	on	on	B-PP	IN	O	30	AMOD	O
O	O	O	1082	1087	human	human	B-NP	JJ	B-cell_line	38	NMOD	B-cell_line
O	O	O	1088	1094	breast	breast	I-NP	NN	I-cell_line	38	NMOD	I-cell_line
O	O	O	1095	1101	cancer	cancer	I-NP	NN	I-cell_line	38	NMOD	I-cell_line
O	O	O	1102	1105	MCF	MCF	I-NP	NN	I-cell_line	38	NMOD	I-cell_line
O	O	O	1105	1106	-	-	B-NP	HYPH	I-cell_line	38	NMOD	I-cell_line
O	O	O	1106	1107	7	7	I-NP	CD	I-cell_line	38	NMOD	I-cell_line
O	O	O	1108	1113	cells	cell	I-NP	NNS	I-cell_line	31	PMOD	I-cell_line
O	O	O	1113	1114	.	.	O	.	O	10	P	O

O	O	O	1115	1122	Whereas	Whereas	B-PP	IN	O	15	VMOD	O
O	O	O	1123	1126	the	the	B-NP	DT	O	4	NMOD	O
O	O	O	1127	1140	hypercalcemic	hypercalcemic	I-NP	JJ	O	4	NMOD	O
O	O	O	1141	1147	effect	effect	I-NP	NN	O	7	SUB	O
O	O	O	1148	1151	for	for	B-PP	IN	O	4	NMOD	O
O	O	O	1152	1160	ZK157202	ZK157202	B-NP	NN	O	5	PMOD	O
O	O	O	1161	1163	is	be	B-VP	VBZ	O	1	SBAR	O
O	O	O	1164	1168	also	also	I-VP	RB	O	7	VMOD	O
O	O	O	1169	1178	increased	increase	I-VP	VBN	O	7	VC	O
O	O	O	1179	1181	10	10	B-NP	CD	O	9	VMOD	O
O	O	O	1181	1182	-	-	O	HYPH	O	10	P	O
O	O	O	1182	1186	fold	fold	B-ADVP	RB	O	10	NMOD	O
O	O	O	1186	1187	,	,	O	,	O	15	P	O
O	O	O	1188	1196	ZK161422	ZK161422	B-NP	NN	O	15	SUB	O
O	O	O	1197	1200	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	1201	1204	the	the	B-NP	DT	O	15	VMOD	O
O	O	O	1205	1209	same	same	I-NP	JJ	O	18	NMOD	O
O	O	O	1210	1217	calcium	calcium	I-NP	NN	O	16	PRD	O
O	O	O	1217	1218	-	-	O	HYPH	O	18	P	O
O	O	O	1218	1228	mobilizing	mobilize	B-VP	VBG	O	18	NMOD	O
O	O	O	1229	1236	potency	potency	B-NP	NN	O	20	OBJ	O
O	O	O	1237	1239	as	as	B-PP	IN	O	20	VMOD	O
O	O	O	1240	1242	VD	VD	B-NP	NN	O	22	PMOD	O
O	O	O	1242	1243	.	.	O	.	O	15	P	O

O	O	O	1244	1252	Moreover	Moreover	B-ADVP	RB	O	9	VMOD	O
O	O	O	1252	1253	,	,	O	,	O	9	P	O
O	O	O	1254	1262	ZK161422	ZK161422	B-NP	NN	O	7	NMOD	O
O	O	O	1262	1263	,	,	O	,	O	7	P	O
O	O	O	1264	1267	but	but	O	CC	O	7	NMOD	O
O	O	O	1268	1271	not	not	O	RB	O	5	DEP	O
O	O	O	1272	1280	ZK157202	ZK157202	B-NP	NN	O	9	SUB	O
O	O	O	1280	1281	,	,	O	,	O	7	P	O
O	O	O	1282	1288	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	O	1289	1299	preference	preference	B-NP	NN	O	9	OBJ	O
O	O	O	1300	1303	for	for	B-PP	IN	O	10	NMOD	O
O	O	O	1304	1308	gene	gene	B-NP	NN	O	13	NMOD	O
O	O	O	1309	1319	activation	activation	I-NP	NN	O	11	PMOD	O
O	O	O	1320	1324	from	from	B-PP	IN	O	13	NMOD	O
O	O	O	1325	1326	a	a	B-NP	DT	O	16	NMOD	O
T3	B-Entity	B-Entity	1327	1335	promoter	promoter	I-NP	NN	B-DNA	14	PMOD	B-DNA
T3	I-Entity	I-Entity	1336	1344	carrying	carry	B-VP	VBG	O	16	NMOD	O
T3	I-Entity	I-Entity	1345	1346	a	a	B-NP	DT	O	21	NMOD	O
T3	I-Entity	I-Entity	1347	1349	VD	VD	I-NP	NN	B-DNA	21	NMOD	B-DNA
T3	I-Entity	I-Entity	1350	1358	response	response	I-NP	NN	I-DNA	21	NMOD	I-DNA
T3	I-Entity	I-Entity	1359	1366	element	element	I-NP	NN	I-DNA	17	OBJ	I-DNA
T3	I-Entity	I-Entity	1367	1371	with	with	B-PP	IN	O	21	NMOD	O
T3	I-Entity	I-Entity	1372	1373	a	a	B-NP	DT	O	25	NMOD	O
T3	I-Entity	I-Entity	1374	1385	palindromic	palindromic	I-NP	JJ	O	25	NMOD	O
T3	I-Entity	I-Entity	1386	1397	arrangement	arrangement	I-NP	NN	O	22	PMOD	O
T3	I-Entity	I-Entity	1398	1400	of	of	B-PP	IN	O	25	NMOD	O
T3	I-Entity	I-Entity	1401	1404	two	two	B-NP	CD	O	31	NMOD	O
T3	I-Entity	I-Entity	1405	1414	hexameric	hexameric	I-NP	JJ	B-DNA	31	NMOD	B-DNA
T3	I-Entity	I-Entity	1415	1423	receptor	receptor	I-NP	NN	I-DNA	31	NMOD	I-DNA
T3	I-Entity	I-Entity	1424	1431	binding	binding	I-NP	NN	I-DNA	31	NMOD	I-DNA
T3	I-Entity	I-Entity	1432	1437	sites	site	I-NP	NNS	I-DNA	26	PMOD	I-DNA
T3	I-Entity	I-Entity	1438	1444	spaced	space	B-VP	VBN	O	31	NMOD	O
T3	I-Entity	I-Entity	1445	1447	by	by	B-PP	IN	O	32	VMOD	O
T3	I-Entity	I-Entity	1448	1449	9	9	B-NP	CD	O	35	NMOD	O
T3	I-Entity	I-Entity	1450	1461	nucleotides	nucleotide	B-NP	NNS	O	33	PMOD	O
T3	I-Entity	I-Entity	1462	1463	(	(	O	(	O	38	DEP	O
T3	I-Entity	I-Entity	1463	1466	IP9	IP9	B-NP	NN	B-protein	38	DEP	B-protein
T3	I-Entity	I-Entity	1466	1467	)	)	O	)	O	35	NMOD	O
O	O	O	1468	1474	rather	rather	B-PP	RB	O	11	PMOD	O
O	O	O	1475	1479	than	than	I-PP	IN	O	39	DEP	O
O	O	O	1480	1483	for	for	B-PP	IN	O	11	PMOD	O
O	O	O	1484	1494	activation	activation	B-NP	NN	O	41	PMOD	O
O	O	O	1495	1499	from	from	B-PP	IN	O	42	NMOD	O
O	O	O	1500	1501	a	a	B-NP	DT	O	46	NMOD	O
T11	B-Entity	B-Entity	1502	1510	response	response	I-NP	NN	O	46	NMOD	O
T11	I-Entity	I-Entity	1511	1518	element	element	I-NP	NN	O	43	PMOD	O
T11	I-Entity	I-Entity	1519	1525	formed	form	B-VP	VBN	O	46	NMOD	O
T11	I-Entity	I-Entity	1526	1528	by	by	B-PP	IN	O	47	VMOD	O
T11	I-Entity	I-Entity	1529	1530	a	a	B-NP	DT	O	51	NMOD	O
T11	I-Entity	I-Entity	1531	1537	direct	direct	I-NP	JJ	O	51	NMOD	O
T11	I-Entity	I-Entity	1538	1544	repeat	repeat	I-NP	NN	O	48	PMOD	O
T11	I-Entity	I-Entity	1545	1551	spaced	space	B-VP	VBN	O	51	NMOD	O
T11	I-Entity	I-Entity	1552	1554	by	by	B-PP	IN	O	52	VMOD	O
T11	I-Entity	I-Entity	1555	1556	3	3	B-NP	CD	O	55	NMOD	O
T11	I-Entity	I-Entity	1557	1568	nucleotides	nucleotide	B-NP	NNS	O	53	PMOD	O
O	O	O	1569	1570	(	(	O	(	O	58	DEP	O
T14	B-Entity	B-Entity	1570	1573	DR3	DR3	B-NP	NN	B-protein	58	DEP	B-protein
O	O	O	1573	1574	)	)	O	)	O	55	NMOD	O
O	O	O	1574	1575	.	.	O	.	O	9	P	O

O	O	O	1576	1580	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	1581	1592	observation	observation	I-NP	NN	O	3	SUB	O
O	O	O	1593	1601	supports	support	B-VP	VBZ	O	0	ROOT	O
O	O	O	1602	1603	a	a	B-NP	DT	O	5	NMOD	O
O	O	O	1604	1609	model	model	I-NP	NN	O	3	OBJ	O
O	O	O	1609	1610	,	,	O	,	O	5	P	O
O	O	O	1611	1613	in	in	B-PP	IN	O	5	NMOD	O
O	O	O	1614	1619	which	which	B-NP	WDT	O	7	PMOD	O
O	O	O	1620	1628	promoter	promoter	B-NP	NN	O	10	NMOD	O
O	O	O	1629	1640	selectivity	selectivity	I-NP	NN	O	11	SUB	O
O	O	O	1641	1649	reflects	reflect	B-VP	VBZ	O	7	SBAR	O
O	O	O	1650	1653	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	1654	1665	selectively	selectively	I-NP	RB	O	14	AMOD	O
O	O	O	1666	1675	increased	increase	I-NP	VBN	O	16	NMOD	O
O	O	O	1676	1693	antiproliferative	antiproliferative	I-NP	JJ	O	16	NMOD	O
O	O	O	1694	1700	effect	effect	I-NP	NN	O	11	OBJ	O
O	O	O	1701	1703	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	1704	1706	VD	VD	B-NP	NN	O	19	NMOD	O
O	O	O	1707	1716	analogues	analogue	I-NP	NNS	O	17	PMOD	O
O	O	O	1716	1717	.	.	O	.	O	3	P	O
